Inside Umbrella | Aktien
Aktienprofil
Johnson & Johnson
Johnson & Johnson bleibt dank starker Pipeline, robuster Cashflows und defensivem Geschäftsmodell ein hochwertiges Healthcare-Investment.
Aktuelle Unternehmensmeldungen
Johnson & Johnson
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* •
Johnson & Johnson
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
• 2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* • 2026 First-Quarter earnings per share…
Johnson & Johnson
Johnson & Johnson reports Q4 and Full-Year 2025 results
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024.